For the first time since its founding, Hugel has exceeded 100 billion KRW in quarterly revenue and 50 billion KRW in quarterly operating profit. On the 6th, Hugel, a total medical aesthetics…

Huons is set to expand its biopharmaceutical R&D and contract development and manufacturing organization (CDMO) services with its acquisition of PanGen, a specialized biopharmaceutical…

The Korean Dementia Association has addressed safety concerns related to the upcoming domestic release of the Alzheimer’s treatment Leqembi (ingredient: lecanemab), stating that the side effects…

Samsung Bioepis has surpassed its total annual revenue from last year within the first three quarters of 2023. The company’s annual revenue is projected to exceed 1.4 trillion KRW (approx. $1…

Boryung is getting closer to achieving 1 trillion KRW ($740 million) in annual sales for the first time, supported by strong third-quarter results. Its growth has been boosted by its co-promotion and…

Yuhan Corporation’s third-quarter operating profit has skyrocketed, primarily due to license revenue from its out-licensed non-small cell lung cancer drug Leclaza. On the 28th, Yuhan reported that…

Following Samsung Biologics’ announcement of its third-quarter results, several securities firms have raised their target stock price for the company. This is largely due to the rapid ramp-up of…

SK bioscience announced that its quadrivalent cell-culture influenza vaccine, SkyCellflu Quadrivalent Pre-filled Syringe(SkyCellflu), has obtained final market authorization from the Indonesian…

Samsung Biologics has made headlines again. On the 22nd, the company announced that it had signed a massive Contract Manufacturing Organization (CMO) deal worth 1.7028 trillion KRW ($1.24 billion)…

It's been two and a half years since OCI became the largest shareholder of Bukwang Pharmaceutical, yet instead of generating synergy, Bukwang's financial performance has continued to falter. On the…